Actinogen Medical Limited (FRA:3AC)
Germany · Delayed Price · Currency is EUR | Market Cap | 99.01M +96.5% |
| Revenue (ttm) | 4.18M -18.4% |
| Net Income | -10.17M |
| EPS | -0.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.0220 |
| Previous Close | 0.0230 |
| Day's Range | 0.0220 - 0.0220 |
| 52-Week Range | 0.0120 - 0.0450 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Actinogen Medical
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]
Financial Performance
In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.
Financial numbers in AUD Financial StatementsNews
Actinogen Medical Transcript: Status update
Alzheimer's care is rapidly evolving with new blood-based biomarkers and modestly effective anti-amyloid therapies, but significant unmet needs remain. Xanamem, an oral therapy targeting brain cortisol, is in late-stage trials and could offer a safer, more convenient alternative if successful, with broad potential applicability.
Actinogen Medical Slides: Status update
Actinogen Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Actinogen Medical Earnings release: Q3 2026
Actinogen Medical released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Actinogen Medical Quarterly report: H1 2026
Actinogen Medical has published its H1 2026 quarterly earnings report on February 25, 2026.
Actinogen Medical Transcript: Investor update
A positive interim analysis cleared safety and efficacy hurdles for the pivotal Alzheimer's trial, with robust funding secured to support operations beyond top-line results in November. Xanamem’s unique mechanism and strong clinical data position it favorably in a market seeking safer, more effective therapies.
Actinogen Medical Slides: Investor update
Actinogen Medical has posted slides in relation to its latest quarterly earnings report, which was published on February 1, 2026.
Actinogen Medical Transcript: Status Update
Final enrollment in the pivotal Alzheimer's trial is complete, with interim analysis set for January and final results due in November next year. Xanamem's unique mechanism and strong safety profile position it as a leading oral therapy, with robust commercial and regulatory momentum.
Actinogen Medical Transcript: Status Update
Pivotal Alzheimer's trial for Xanamem® is fully enrolled, with interim analysis in January and final results expected mid-Q4 next year. Strong FDA support, robust financial runway, and high physician interest position the program for major milestones and potential partnerships.
Actinogen Medical Earnings release: Q1 2026
Actinogen Medical released its Q1 2026 earnings on October 22, 2025, summarizing the period's financial results.
Actinogen Medical Slides: Corporate Presentation
Actinogen Medical has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2025.